Literature DB >> 24261650

Does removal of the primary tumor in metastatic breast cancer improve survival?

Omar M Rashid1, Kazuaki Takabe.   

Abstract

Although relative survival for breast cancer has improved in recent years, patients who present with metastatic disease have a less than 30% 5-year survival. Thus, improvements in treatment for these patients have the potential to have a significant impact on outcomes. Historically, removal of the primary breast tumor has been offered to these patients only for palliation. However, there have been recent reports that removal of the primary tumor may improve survival. Here, we review the theories and data at the center of the debate, the landmark studies that historically guided treatment, the retrospective data that revisited the role of removal of the primary tumor, as well as the latest advances in basic science and the accruing clinical studies to provide for future directions in this field. Although the definitive role of removal of the primary tumor in metastatic breast cancer is not settled, it is critical to understand the complexities of this debate in order to make further gains in breast cancer survivorship.

Entities:  

Mesh:

Year:  2013        PMID: 24261650      PMCID: PMC3922396          DOI: 10.1089/jwh.2013.4517

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  31 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  New perspectives in clinical oncology from angiogenesis research.

Authors:  J Folkman
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

3.  Does aggressive local therapy improve survival in metastatic breast cancer?

Authors:  Seema A Khan; Andrew K Stewart; Monica Morrow
Journal:  Surgery       Date:  2002-10       Impact factor: 3.982

4.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.

Authors:  G R Blumenschein; A DiStefano; J Caderao; B Fristenberg; J Adams; L H Schweichler; L Drinkard
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

6.  Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.

Authors:  Omar M Rashid; Masayuki Nagahashi; Subramaniam Ramachandran; Laura Graham; Akimitsu Yamada; Sarah Spiegel; Harry D Bear; Kazuaki Takabe
Journal:  Surgery       Date:  2013-03-13       Impact factor: 3.982

7.  Does local surgery have a role in the management of stage IV breast cancer?

Authors:  A R Carmichael; E D C Anderson; U Chetty; J M Dixon
Journal:  Eur J Surg Oncol       Date:  2003-02       Impact factor: 4.424

8.  Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis.

Authors:  Ryan C Fields; Donna B Jeffe; Kathryn Trinkaus; Qin Zhang; Carey Arthur; Rebecca Aft; Jill R Dietz; Timothy J Eberlein; William E Gillanders; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2007-08-09       Impact factor: 5.344

9.  Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.

Authors:  Erika A Danna; Pratima Sinha; Mileka Gilbert; Virginia K Clements; Beth A Pulaski; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data.

Authors:  Jennifer Gnerlich; Donna B Jeffe; Anjali D Deshpande; Courtney Beers; Christina Zander; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2007-05-24       Impact factor: 5.344

View more
  13 in total

Review 1.  Animal models for exploring the pharmacokinetics of breast cancer therapies.

Authors:  Omar M Rashid; Kazuaki Takabe
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-11-21       Impact factor: 4.481

2.  Conflicting roles of EGFR expression by subtypes in breast cancer.

Authors:  Masanori Oshi; Shipra Gandhi; Yoshihisa Tokumaru; Li Yan; Akimitsu Yamada; Ryusei Matsuyama; Takashi Ishikawa; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2021-10-15       Impact factor: 5.942

3.  Modified breast cancer model for preclinical immunotherapy studies.

Authors:  Eriko Katsuta; Stephanie C DeMasi; Krista P Terracina; Sarah Spiegel; Giao Q Phan; Harry D Bear; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-06-08       Impact factor: 2.192

4.  Local Surgery Improves Survival in Patients with Primary Metastatic Breast Cancer: A Population-Based Study.

Authors:  Yuan-Yuan Zhao; He-Fen Sun; Xue-Li Yang; Yang Zhao; Meng-Ting Chen; Wei Jin
Journal:  Breast Care (Basel)       Date:  2019-11-21       Impact factor: 2.860

5.  Murine breast cancer mastectomy model that predicts patient outcomes for drug development.

Authors:  Eriko Katsuta; Omar M Rashid; Kazuaki Takabe
Journal:  J Surg Res       Date:  2017-11       Impact factor: 2.192

6.  Exposure to 60% oxygen promotes migration and upregulates angiogenesis factor secretion in breast cancer cells.

Authors:  Peter D Crowley; Vivian Stuttgen; Emma O'Carroll; Simon A Ash; Donal J Buggy; Helen C Gallagher
Journal:  Med Gas Res       Date:  2018-01-22

7.  Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.

Authors:  Guo-Li Shao; Meng-Chuan Wang; Xu-Long Fan; Lin Zhong; Shu-Feng Ji; Guo Sang; Shui Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

8.  A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer.

Authors:  O M Rashid; D Maurente; K Takabe
Journal:  Chemotherapy (Los Angel)       Date:  2016-05-30

9.  Cryoablation of Primary Breast Cancer in Patients with Metastatic Disease: Considerations Arising from a Single-Centre Data Analysis.

Authors:  Claudio Pusceddu; Luca Melis; Nicola Ballicu; Paolo Meloni; Valeria Sanna; Alberto Porcu; Alessandro Fancellu
Journal:  Biomed Res Int       Date:  2017-10-19       Impact factor: 3.411

10.  Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.

Authors:  Jianqin Lu; Xiangsheng Liu; Yu-Pei Liao; Xiang Wang; Ayman Ahmed; Wen Jiang; Ying Ji; Huan Meng; Andre E Nel
Journal:  ACS Nano       Date:  2018-10-16       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.